المؤلفون: Andrew K. Dilger (2461681), Kumar B. Pabbisetty (1601845), James R. Corte (1705543), Indawati De Lucca (11407452), Tianan Fang (1705540), Wu Yang (414613), Donald J. P. Pinto (8212503), Yufeng Wang (274657), Yeheng Zhu (1870663), Arvind Mathur (144120), Jianqing Li (523126), Xiaoping Hou (3225315), Daniel Smith (6120), Dawn Sun (1565869), Huiping Zhang (135186), Subramaniam Krishnananthan (1402561), Dauh-Rurng Wu (1402558), Joseph E. Myers (2383984), Steven Sheriff (1601854), Karen A. Rossi (1601821), Silvi Chacko (10732002), Joanna J. Zheng (1601842), Michael A. Galella (2065051), Theresa Ziemba (10048686), Elizabeth A. Dierks (2443834), Jeffrey M. Bozarth (1601851), Yiming Wu (295996), Earl Crain (11407455), Pancras C. Wong (1601836), Joseph M. Luettgen (1550428), Ruth R. Wexler (1550446), William R. Ewing (1870717)

مصطلحات موضوعية: Biochemistry, Medicine, Genetics, Pharmacology, Biotechnology, Hematology, Infectious Diseases, Virology, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, coagulation cascade thought, amplify thrombin generation, orally bioavailable inhibitor, milvexian b, k <, , thromboembolic disorders, superior efficacy, solubility resulted, preclinical models, pk properties, oral administration, limited role, irreversible inhibitors, human genetics, free fraction, factor xia, clinical studies, clinical candidate, antithrombotic agent

Relation: https://figshare.com/articles/journal_contribution/Discovery_of_Milvexian_a_High-Affinity_Orally_Bioavailable_Inhibitor_of_Factor_XIa_in_Clinical_Studies_for_Antithrombotic_Therapy/16586658

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c00613.s002

المؤلفون: Andrew K. Dilger (2461681), Kumar B. Pabbisetty (1601845), James R. Corte (1705543), Indawati De Lucca (11407452), Tianan Fang (1705540), Wu Yang (414613), Donald J. P. Pinto (8212503), Yufeng Wang (274657), Yeheng Zhu (1870663), Arvind Mathur (144120), Jianqing Li (523126), Xiaoping Hou (3225315), Daniel Smith (6120), Dawn Sun (1565869), Huiping Zhang (135186), Subramaniam Krishnananthan (1402561), Dauh-Rurng Wu (1402558), Joseph E. Myers (2383984), Steven Sheriff (1601854), Karen A. Rossi (1601821), Silvi Chacko (10732002), Joanna J. Zheng (1601842), Michael A. Galella (2065051), Theresa Ziemba (10048686), Elizabeth A. Dierks (2443834), Jeffrey M. Bozarth (1601851), Yiming Wu (295996), Earl Crain (11407455), Pancras C. Wong (1601836), Joseph M. Luettgen (1550428), Ruth R. Wexler (1550446), William R. Ewing (1870717)

مصطلحات موضوعية: Biochemistry, Medicine, Genetics, Pharmacology, Biotechnology, Hematology, Infectious Diseases, Virology, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, coagulation cascade thought, amplify thrombin generation, orally bioavailable inhibitor, milvexian b, k <, , thromboembolic disorders, superior efficacy, solubility resulted, preclinical models, pk properties, oral administration, limited role, irreversible inhibitors, human genetics, free fraction, factor xia, clinical studies, clinical candidate, antithrombotic agent

Relation: https://figshare.com/articles/dataset/Discovery_of_Milvexian_a_High-Affinity_Orally_Bioavailable_Inhibitor_of_Factor_XIa_in_Clinical_Studies_for_Antithrombotic_Therapy/16586655

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c00613.s001